Geographic Atrophy

Geographic atrophy (GA) is the advanced, late stage of the dry form of age-related macular degeneration (AMD). In GA, patches of light-sensing cells in the central part of the retina—the macula—gradually waste away, leaving sharply defined areas of tissue loss that look like islands on a map when viewed by an eye doctor Macular Societymacular.org. The macula is responsible for our sharp, central vision, which lets us read, recognize faces, and drive. As GA advances, those patches enlarge and sometimes merge, causing increasing loss of central vision while peripheral vision remains intact.

Geographic atrophy (GA) is the advanced, “dry” form of age-related macular degeneration (AMD) in which critical cells in the retina—photoreceptors, retinal pigment epithelium (RPE), and underlying choriocapillaris—gradually waste away, leaving well-defined patches of retinal thinning. Patients with GA experience a slow but relentless loss of central vision, making tasks like reading, recognizing faces, and driving increasingly difficult BrightFocus FoundationPMC. In simple terms, GA is like “wearing away” of the retina’s most important area for sharp, clear sight, and currently affects over 5 million people worldwide, with no way to reverse the damage once it occurs Wikipedia.

GA affects more than 5 million people worldwide and about 1 million in the United States Foundation Fighting BlindnessVerywell Health. It most commonly appears after age 60 and becomes more frequent with each decade. Unlike wet AMD—where abnormal blood vessels leak under the retina and sometimes bleed—GA progresses more slowly but with no effective cure approved to fully reverse its damage. New treatments approved by the FDA in 2023 and 2024 can slow the progression in some patients, but once retinal cells die, they do not regenerate.

At its core, GA involves death of two critical cell layers in the macula:

• Photoreceptors, which convert light into electrical signals.

• Retinal pigment epithelium (RPE), which nourishes photoreceptors and removes waste.

When these cells die, the overlying photoreceptors also perish. This cell loss appears as well-demarcated atrophic areas on imaging. Early on, GA may spare the very center (the fovea), allowing some fine vision to remain until the atrophy reaches that spot ScienceDirect. Over time, vision decline can significantly impact daily activities, reducing quality of life and independence.

Risk factors for GA largely overlap with those for AMD in general: advancing age, family history, smoking, poor diet, and genetic variants in the complement system (especially the CFH gene). Oxidative stress, chronic inflammation, and impaired blood flow in the choroid (the layer beneath the retina) all contribute to RPE dysfunction. Clinically, GA is diagnosed through a combination of vision tests, detailed eye examination, and specialized imaging that highlights areas of atrophy.

---

Types of Geographic Atrophy

Geographic atrophy can present in several patterns. Classifying these types helps doctors predict progression and tailor monitoring:

1. Foveal-sparing GA
   In this type, the atrophic patches avoid the fovea (the very center of the macula) for a time. Patients may retain relatively good central vision until atrophy expands into the fovea.

2. Foveal-involving GA
   Here, atrophic areas include the fovea from the start or reach it early. Central vision loss tends to be greater and may progress more quickly.

3. Unifocal GA
   A single, large patch of atrophy appears. It may grow concentrically, enlarging outward from one focus.

4. Multifocal GA
   Multiple smaller atrophic spots appear in different parts of the macula. Over time, these spots can merge into a larger area.

5. Peripapillary GA
   Less common, this type involves atrophy that starts around the optic nerve head and may spread into the macula.

Each pattern carries its own pace of progression and visual prognosis. Doctors use imaging to identify these patterns and track changes over time ScienceDirect.

---

Causes of Geographic Atrophy

1. Advancing Age
   The strongest risk factor. After age 60, cumulative oxidative damage and cellular wear make RPE and photoreceptors vulnerable.

2. Genetic Variants
   Changes in genes such as CFH, C3, and ARMS2 affect the complement system, leading to chronic inflammation in the retina.

3. Smoking
   Tobacco toxins increase oxidative stress and damage blood vessels supplying the retina, accelerating atrophy.

4. Poor Diet
   Low intake of antioxidants (vitamins C, E, zinc, lutein, zeaxanthin) fails to protect retinal cells from free radical damage.

5. High-fat Diet
   Diets rich in saturated fats and cholesterol promote drusen (lipid and protein deposits) formation under the RPE, a hallmark of AMD.

6. Obesity
   Excess body fat is linked to systemic inflammation and impaired blood flow, raising GA risk.

7. Hypertension
   High blood pressure damages small retinal and choroidal vessels, worsening nutrient delivery to the macula.

8. Hyperlipidemia
   Elevated blood lipids contribute to drusen formation and complement activation in the retina.

9. Chronic Sunlight Exposure
   UV and blue light can damage photoreceptors and RPE through phototoxicity over decades.

10. Light-sensing Cell Dysfunction
    Mitochondrial dysfunction in RPE cells reduces energy for waste removal, leading to cell death.

11. Complement System Over-activation
    An overactive immune response in the retina causes ongoing low-grade inflammation and RPE injury.

12. Drusen Accumulation
    Large or confluent drusen increase local stress on RPE and photoreceptors, pushing them toward atrophy.

13. Choroidal Thinning
    Loss of choroidal blood flow starves RPE of oxygen and nutrients.

14. Bruch’s Membrane Changes
    Thickening or calcification of this layer beneath the RPE impairs waste removal and nutrient flow.

15. Foveal Hypo-perfusion
    Reduced blood flow in the foveal region hastens photoreceptor loss once atrophy begins.

16. Oxidative Stress
    An imbalance between free radicals and antioxidants damages cellular DNA, proteins, and membranes in the macula.

17. Inflammatory Cytokines
    Chronic release of cytokines like IL-6 and TNF-α in the retina promotes RPE apoptosis.

18. Systemic Cardiovascular Disease
    Atherosclerosis and heart disease often coexist with AMD and GA due to shared vascular risk factors.

19. Diabetes Mellitus
    High blood sugar damages small vessels and increases inflammation, compounding retinal stress.

20. Male Gender
    Some studies show a slightly higher risk of GA progression in men, possibly linked to hormonal and lifestyle differences.

Each cause contributes through overlapping pathways of inflammation, oxidative damage, and impaired blood flow. Addressing modifiable risks—quitting smoking, improving diet, controlling blood pressure and lipids—can slow progression.

---

Symptoms of Geographic Atrophy

1. Blurred Central Vision
   Straightforward loss of sharp sight when looking directly at objects, making reading and recognizing faces difficult.

2. Scotoma (Blind Spot)
   A dark or gray patch in the center of vision that may grow over time.

3. Difficulty Reading
   Words appear faint, missing letters, or seem to jump on the page, requiring very bright light.

4. Trouble Recognizing Faces
   Central vision loss makes identifying people at a distance or in crowds hard.

5. Need for Brighter Light
   Tasks that once felt normal need extra illumination as contrast sensitivity declines.

6. Reduced Color Perception
   Colors may look less vivid or slightly washed out, especially in low light.

7. Visual Distortions
   While more common in wet AMD, some GA patients notice slight waviness or bending of straight lines.

8. Difficulty Driving
   Central vision loss hampers reading road signs and tracking vehicles ahead.

9. Problems with Low-light Conditions
   Dusk or indoor lighting may become inadequate for detailed tasks.

10. Photophobia (Light Sensitivity)
    Bright lights may feel uncomfortable or glare more intense than before.

11. Poor Contrast Sensitivity
    Harder to distinguish objects from their background, such as dark clothing on a dark sofa.

12. Visual Fatigue
    Eyes tire quickly when trying to focus centrally, leading to headaches or eyestrain.

13. Skilled Task Difficulty
    Hobbies like sewing, knitting, or detailed crafts become challenging.

14. Worsening over Months to Years
    Symptoms slowly worsen, often without sudden changes, making early detection hard without testing.

15. One Eye Ahead of the Other
    GA may start in one eye before the other, so patients may not notice until both eyes are involved.

Because peripheral vision remains, patients seldom report “total blindness,” but central tasks become severely compromised. Early recognition of these symptoms can prompt an eye exam before irreversible damage spreads.

---

 Diagnostic Tests for Geographic Atrophy

Physical Examination & Manual Tests

1. Visual Acuity Test
   Measures clarity of central vision using standardized eye charts at 20 feet. Poor results suggest macular involvement.

2. Amsler Grid Test
   A simple grid of lines patients view to detect wavy, missing, or distorted central squares. Changes indicate macular damage.

3. Dilated Fundus Examination
   Eye drops enlarge the pupil so the doctor can examine the retina with an ophthalmoscope, looking for atrophic patches.

4. Slit-Lamp Biomicroscopy
   A special microscope illuminates the retina via handheld lenses, allowing detailed views of the macula and RPE.

5. Red-free (Green) Filter Exam
   Using a green light filter highlights abnormalities in the retina and can better show areas of atrophy.

6. In-office Fundus Photography
   High-resolution photos document the size and shape of atrophic lesions over time.

Laboratory & Pathological Tests

1. Genetic Testing
   Identifies variants in complement genes (CFH, C3, etc.) that raise GA risk, useful for research and potential future therapies.

2. Lipid Profile
   Blood tests measuring cholesterol and triglycerides assess systemic drusen risk factors.

3. Inflammatory Markers
   C-reactive protein (CRP) and interleukins can be elevated in patients with active AMD inflammation.

4. Oxidative Stress Markers
   Blood or tear-film assays of antioxidant vitamins (E, C, lutein) gauge nutritional protection levels.

Electrodiagnostic Tests

1. Full-Field Electroretinography (ffERG)
   Measures overall retinal electrical response to light. In GA, outer retinal signals are reduced.

2. Pattern Electroretinography (pERG)
   Assesses macular ganglion cell function. Abnormal pERG indicates central retinal dysfunction before visible atrophy.

Imaging Tests

1. Optical Coherence Tomography (OCT)
   Cross-sectional “slice” images of the retina reveal thinning of photoreceptor and RPE layers at atrophic sites American Society of Retina SpecialistsMayo Clinic.

2. Fundus Autofluorescence (FAF)
   Highlights areas of lipofuscin buildup and RPE loss; atrophic zones appear dark against a bright background.

3. Optical Coherence Tomography Angiography (OCTA)
   Visualizes blood flow in retinal and choroidal vessels without dye. Flow deficits often underlie GA patches.

4. Fluorescein Angiography (FA)
   Injected dye highlights blood vessels; areas of atrophy show window defects where RPE is absent.

5. Indocyanine Green Angiography (ICGA)
   A different dye examines deeper choroidal circulation, identifying hypoperfusion linked to GA progression.

6. Infrared Reflectance Imaging
   Infrared light penetrates deeper retinal layers; atrophic areas often reflect differently from healthy tissue.

7. Near-Infrared Autofluorescence
   Similar to FAF but uses longer wavelengths, sometimes showing atrophy margins more clearly.

8. Adaptive Optics Imaging
   High-resolution images of individual photoreceptors reveal early cell loss before large atrophic patches form.

Non-Pharmacological Treatments

1. Low Vision Rehabilitation
   Programs led by specialists teach patients to maximize remaining vision through techniques like eccentric viewing and contrast enhancement. Studies show these services help maintain functional vision and improve quality of life over two years PMCMedical News Today.

2. Photobiomodulation Therapy (PBM)
   PBM uses carefully delivered low-level light (e.g., near-infrared) to stimulate cellular repair and reduce inflammation. Clinical trials (e.g., LIGHTSITE III) report anatomical and functional benefits in early dry AMD, suggesting potential to slow GA progression PubMedClinicalTrials.gov.

3. Smoking Cessation
   Quitting smoking cuts oxidative stress on retinal cells and can slow atrophy enlargement. Lifestyle-change studies recommend cessation as a key preventive measure for AMD and GA Verywell HealthPrevent Blindness.

4. Ultraviolet and Blue-Light Protection
   Wearing UV-blocking sunglasses and blue-light filtering lenses reduces light-induced oxidative damage to the retina, preserving RPE health over time Verywell HealthPrevent Blindness.

5. Healthy Diet and Weight Management
   A balanced diet rich in fruits, vegetables, and lean proteins supports overall eye health. Achieving and maintaining a healthy weight reduces systemic inflammation that can exacerbate GA Verywell HealthPrevent Blindness.

6. Blood Pressure and Cholesterol Control
   Keeping blood pressure and cholesterol in check protects tiny retinal vessels and reduces complement-mediated damage, slowing atrophy growth Prevent Blindness.

7. Physical Exercise
   Regular moderate exercise improves circulation to the retina and lowers chronic inflammation, offering indirect protection against GA progression Prevent Blindness.

8. Occupational and Home Environment Modification
   Simple changes—brighter, glare-free lighting; high-contrast markings around the home; and unbreakable magnifiers—help patients perform daily tasks more safely and independently Verywell Health.

9. Adaptive Devices and Technology
   Tools like handheld magnifiers, electronic video magnification systems (CCTVs), screen-reader software, and implantable miniature telescopes expand visual function, allowing continued reading and face recognition Verywell Health.

10. Orientation and Mobility Training
    Training improves safe navigation by teaching techniques such as using peripheral vision and tactile cues, reducing fall risk and boosting confidence Verywell Health.

11. Eccentric Viewing Training
    Patients learn to use non-atrophic parts of the retina to fixate on objects, slowing functional decline Medical News Today.

12. Microperimetry-Guided Vision Training
    Tailored exercises based on microperimetry maps help strengthen residual macular areas, enhancing reading speed and contrast sensitivity Medical News Today.

13. Tele-ophthalmology Monitoring
    Remote vision testing and imaging allow frequent check-ups without in-person visits, facilitating early detection of functional changes Verywell Health.

14. Nutritional Counseling
    Guidance on nutrient-rich foods supports supplement programs and overall eye health, reinforcing adherence to dietary recommendations Prevent Blindness.

15. Support Groups and Patient Education
    Connecting with peers and learning about coping strategies reduces anxiety and promotes proactive vision care Prevent Blindness.

16. Cognitive-Behavioral Therapy (CBT)
    Addressing emotional stress associated with vision loss can improve mental well-being and motivation to follow treatment plans Prevent Blindness.

17. Mindfulness and Stress Reduction
    Techniques like meditation and yoga reduce systemic inflammation that can worsen retinal degeneration Prevent Blindness.

18. Vocational Rehabilitation
    Career counseling and workplace adaptations help maintain employment and independence despite visual impairment Prevent Blindness.

19. Assistive Mobile Apps
    Smartphone apps offering text-to-speech, magnification, and contrast adjustment give patients practical tools for everyday tasks Verywell Health.

20. Gene Panel Testing for Risk Stratification
    Genetic testing for complement pathway variants can inform personalized risk-reduction strategies, although its clinical role is still evolving PentaVision.

Drug Treatments

1. Pegcetacoplan (Syfovre)

   • Class: Complement C3 inhibitor

   • Dosage/Time: 15 mg (0.1 mL of 150 mg/mL) intravitreal injection every 25–60 days

   • Purpose: Slow enlargement of GA lesions

   • Mechanism: Blocks C3 activation, reducing complement-mediated cell death

   • Side Effects: Injection-site inflammation, endophthalmitis risk FDA Access Data.

2. Avacincaptad Pegol (Izervay)

   • Class: Complement C5 inhibitor (RNA aptamer)

   • Dosage/Time: 2 mg (0.1 mL) intravitreal injection monthly

   • Purpose: Reduce GA lesion growth

   • Mechanism: Inhibits C5, preventing formation of the membrane attack complex

   • Side Effects: Eye discomfort, endophthalmitis FDA Access Data.

3. Lampalizumab

   • Class: Complement factor D inhibitor (antigen-binding fragment)

   • Dosage/Time: 10 mg intravitreal injection every 4–6 weeks

   • Purpose: Trial drug aimed at slowing GA (proved ineffective)

   • Mechanism: Blocks factor D in the alternative complement pathway

   • Side Effects: Rare intraocular pressure increases, injection-related events JAMA NetworkPubMed.

4. ANX007

   • Class: C1q inhibitor (antigen-binding fragment)

   • Dosage/Time: 5 mg intravitreal injection monthly

   • Purpose: Preserve visual acuity in GA patients

   • Mechanism: Blocks classical complement activation at C1q, protecting photoreceptors

   • Side Effects: Mild injection-site reactions American Academy of OphthalmologyIOVS.

5. GT005 (PPY988)

   • Class: Gene therapy—AAV2 vector delivering complement factor I

   • Dosage/Time: Single subretinal injection

   • Purpose: Increase CFI production, down-regulate overactive complement

   • Mechanism: Gene delivery enables endogenous CFI expression

   • Side Effects: Surgical risks; discontinued after early futility analysis Retina TodayNovartis.

6. JNJ-1887 (HMR59)

   • Class: AAV vector gene therapy encoding CD59

   • Dosage/Time: Single subretinal injection

   • Purpose: Protect against complement-mediated cell damage

   • Mechanism: Expresses CD59 to inhibit membrane attack complex formation

   • Side Effects: Procedural risks; under phase 2b evaluation Retina Today.

7. RG6501 (OpRegen)

   • Class: Cell therapy—human embryonic stem cell-derived RPE patch

   • Dosage/Time: Single subretinal implantation

   • Purpose: Replace lost RPE cells and support photoreceptors

   • Mechanism: Transplanted RPE integrate and restore retinal support

   • Side Effects: Immunosuppression, surgical risks Retina Today.

8. Brimonidine Drug Delivery System (Brimo DDS Gen 2)

   • Class: α₂-adrenergic agonist implant

   • Dosage/Time: 400 μg intravitreal implant every 3 months

   • Purpose: Neuroprotection and reduced GA progression

   • Mechanism: Activates α₂ receptors, up-regulates survival pathways in photoreceptors

   • Side Effects: Implant-related ocular events; early termination due to slow GA progression PubMed+1PubMed+1.

9. Sirolimus (Rapamycin)

   • Class: mTOR inhibitor, immunosuppressive agent

   • Dosage/Time: 440 μg (20 µL) intravitreal injection monthly

   • Purpose: Trial drug aimed at modulating inflammatory pathways in GA

   • Mechanism: Inhibits mTOR, reducing microglial activation and complement factors

   • Side Effects: No significant difference in GA growth; injection-related inflammation PubMedPMC.

10. Emixustat Hydrochloride

    • Class: Visual cycle modulator (oral small molecule)

    • Dosage/Time: 2.5–10 mg orally once daily

    • Purpose: Reduce toxic retinal byproducts and slow GA enlargement

    • Mechanism: Inhibits RPE65, decreasing formation of A2E and lipofuscin

    • Side Effects: Delayed dark adaptation, mild systemic complaints; failed to meet primary endpoint PubMed+1PubMed+1.

Dietary Molecular Supplements

1. Vitamin C (500 mg/day) – Powerful antioxidant that neutralizes free radicals in the retina, reducing oxidative damage National Institutes of Health (NIH)Macular Society.

2. Vitamin E (400 IU/day) – Lipid-soluble antioxidant that protects photoreceptor membranes from peroxidation National Institutes of Health (NIH)Macular Society.

3. Lutein (10 mg/day) – Filters blue light and supports macular pigment density, improving contrast sensitivity National Institutes of Health (NIH)Wikipedia.

4. Zeaxanthin (2 mg/day) – Complements lutein in macular protection by scavenging singlet oxygen National Institutes of Health (NIH)Wikipedia.

5. Zinc (80 mg/day) – Cofactor for superoxide dismutase, essential for antioxidant enzyme activity National Institutes of Health (NIH)Macular Society.

6. Copper (2 mg/day) – Prevents copper-deficiency anemia associated with high zinc intake in AREDS2 National Institutes of Health (NIH)Macular Society.

7. Omega-3 Fatty Acids (DHA/EPA) (1 g/day) – Anti-inflammatory, maintains photoreceptor membrane integrity Real Simple.

8. Saffron (Crocin/Crocetin) (20 mg/day) – Antioxidant that improves photoreceptor function and visual acuity in early AMD PubMedPMC.

9. Coenzyme Q10 (100 mg/day) – Mitochondrial antioxidant that supports retinal cell energy and reduces oxidative stress PubMedMDPI.

10. Ginkgo Biloba Extract (120 mg/day) – Promotes microcirculation and antioxidant protection of RPE cells PentaVision.

Regenerative and “Hard Immunity” Drugs

1. OpRegen (RG6501) – Stem cell-derived RPE patch (subretinal implant) to replace atrophied RPE Retina Today.

2. ANX007 – C1q inhibitor (see “Drug Treatments”) for classical complement blockade American Academy of Ophthalmology.

3. GT005 – Gene therapy delivering complement factor I (see “Drug Treatments”) Retina Today.

4. OpRegen – RPE cell therapy (same as RG6501) Retina Today.

5. Emixustat – Visual cycle modulator (see “Drug Treatments”) PubMed.

6. Experimental iPSC-Derived RPE – Autologous pluripotent stem cell-derived RPE transplants under study for safety and feasibility National Eye Institute.

Surgical Procedures

1. Macular Translocation
   Rotates a healthier portion of the retina over the fovea via 360° peripheral retinectomy; aims to place functional retina over central vision area PubMed.

2. RPE-Choroid Transplantation
   Autologous RPE and choroid tissue grafted under the macula to replace atrophied layers; designed to restore RPE function PubMed.

3. Retinal Prosthesis (Implantable Telescope)
   Miniature telescope surgically implanted between lens and retina to magnify images onto healthier retinal areas, improving reading and face-recognition tasks Verywell Health.

4. Subretinal Cell Implantation
   Direct placement of stem cell-derived RPE into the subretinal space to repopulate lost cells and support photoreceptors National Eye Institute.

5. Vitrectomy with Gene-Delivery Ports
   Pars plana vitrectomy with subretinal injection ports facilitates delivery of gene therapies (e.g., GT005) to target RPE cells Retina Today.

Prevention Strategies

1. Quit smoking and avoid secondhand smoke

2. Wear UV- and blue-light-blocking eyewear outdoors

3. Follow a Mediterranean-style diet rich in leafy greens, fish, and nuts

4. Maintain healthy blood pressure and cholesterol levels

5. Exercise regularly (≥150 minutes/week of moderate activity)

6. Control weight and blood sugar if diabetic

7. Manage cardiovascular risk factors (e.g., statin therapy as indicated)

8. Schedule regular eye exams for early detection

9. Keep indoor lighting evenly bright to reduce eye strain

10. Stay informed about new therapies and clinical trials

When to See a Doctor

• Noticing blurry or blank spots in central vision

• Difficulty reading after years of clear vision

• Trouble recognizing faces or seeing fine details

• Rapid increase in size or number of central blind spots

• Worsening contrast sensitivity and night vision

• Sudden onset of distortions (metamorphopsia)

• Changes interfering with daily tasks like driving

• New floaters or flashes of light (rule out wet AMD)

• Persistent eye pain or redness after an injection

• Any significant vision change requiring prompt evaluation

“Eat and Avoid” Guidelines

Eat More:

1. Leafy greens (spinach, kale)

2. Fatty fish (salmon, mackerel)

3. Colorful fruits (berries, bell peppers)

4. Nuts and seeds (walnuts, flaxseed)

5. Eggs (lutein and zeaxanthin)

6. Whole grains (low glycemic index)

7. Legumes (beans, lentils)

8. Olive oil (healthy fats)

9. Citrus fruits (vitamin C)

10. Colorful vegetables (carrots, sweet potatoes)

Avoid:

1. Processed and trans fats

2. High-sugar foods and beverages

3. Excessive red meat and processed meats

4. Refined carbohydrates (white bread, pastries)

5. High-sodium snacks

6. Excessive alcohol intake

7. Foods low in nutrient density (chips, candies)

8. High-GI foods that spike blood sugar

9. Artificial sweeteners and additives

10. Smoking and secondhand smoke exposure

Frequently Asked Questions

1. What exactly is geographic atrophy?
   GA is the advanced stage of dry AMD marked by loss of RPE and photoreceptors, causing central vision loss.

2. How fast does GA progress?
   On average, GA lesions grow by about 2 mm² per year, though rates vary by individual risk factors PubMed.

3. Can GA be cured?
   Currently, GA cannot be reversed; treatments aim only to slow its progression.

4. Are the new injections painful?
   Most patients report only mild discomfort during intravitreal injections, similar to a quick pinch.

5. How often do I need to get injections?
   Approved drugs like Syfovre are given every 1–2 months; others vary from monthly to quarterly.

6. Do supplements help if I already have GA?
   AREDS2 supplements can slow progression even in late dry AMD stages National Institutes of Health (NIH).

7. Will my peripheral vision stay normal?
   Yes—GA affects central vision; peripheral vision typically remains intact.

8. Can I drive with GA?
   Many patients with mild GA continue to drive safely; as GA worsens, vision aids and occupational assessment are recommended.

9. Is GA hereditary?
   Genetic factors in the complement pathway increase risk, but lifestyle also plays a major role.

10. Can laser or radiation therapy help?
    No proven benefit; most laser approaches target wet AMD, not GA.

11. What is the difference between wet AMD and GA?
    Wet AMD involves abnormal blood vessel growth; GA is characterized by tissue atrophy without bleeding.

12. Are there clinical trials I can join?
    Yes—trials for PBM, gene therapies (ANX007, GT005), stem cell transplants, and complement inhibitors are ongoing.

13. When should I test my vision at home?
    Monthly self-monitoring with an Amsler grid is advised to detect changes early.

14. Does light exposure worsen GA?
    Chronic high-energy light can add oxidative stress; wearing protective lenses is recommended.

15. How can I cope emotionally with GA?
    Support groups, counseling, and vision rehabilitation programs help manage the psychological impact.

 

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 04, 2025.